natgillin/translations-raw huggingface dataset:
The method of embodiment 1, wherein the first average oil droplet size is 5000 nm or less. 
Postupak prema zahtjevu 1, naznačen time da je prva prosječna veličina uljne kapljice 5000 nm ili manje.
The method according to claim 18, wherein each fraction has particles at minimum/maximum particle size ratio of 1:3. The method according to claim 18, wherein each fraction has particles at minimum/maximum particle size ratio of 1:2. 
Postupak prema zahtjevu 13, naznačen time da je omjer minimalne/maksimalne veličine čestica unutar frakcije 1:4, poželjno 1:3, a još poželjnije 1:2.
the process of claims 10 to 15, wherein the EGF is dissolved in an aqueous solution containing a cationic surfactant with a concentration above its critical micellar concentration. 
Posupak iz bilo kojeg od patentnih zahtjeva 7-9, pri čemu se EGF rastvara u vodenom rastvoru koji sadrži kationski surfaktant s koncentracijom iznad njegove kritične micelarne koncentracije.
D and D1 are independently selected from a bond or NRc; A is optionally substituted aryl or optionally substituted heteroaryl; 
D i D' su nezavisno izabrani od veze ili NR'"; A je izborno supstituirani biciklični heteroaril;
The method of claim 7, wherein the biological sample is derived from a human, rodent, nonhuman primate, rabbit, or dog. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se biološki uzorak dobiva iz čovjeka, glodavca, neljudskog primata, kunića ili psa.
A container according to any preceding claim, wherein the distance between the upper surface of the denesting area and the base of the tray is shorter than the distance between the upper surface of the flange and the base. 
Posuda prema patentnom zahtjevu 7, pri čemu je razmak između gornje površine zone za odvajanje 1 osnove posude manji od razmaka između gornje površine prirubnice i osnove.
The dry powder formulation according to claim 1, wherein said magnesium stearate coats the surface of said fine particles (a) in such a way that the extent of the surface coating is at least of 10%. 
Formulacija suhog praška prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time da magnezijev stearat oblaže površinu ekscipijensa čestica a) na takav način da se oblaganjem poveća površina za najmanje 50%.
The formulation of claim 21, wherein the pH buffered saline solution contains sodium chloride, 
Formulacija u skladu s patentnim zahtjevom 21, naznačena time što sol u fiziološkoj otopini s puferiranim pH sadrži natrijev klorid.
The construct for the use of claim 1 or 2, wherein said acute lymphoblastic leukemia (ALL) is relapsed ALL or relapsed ALL refractory to chemotherapy and/or hematopoietic stem cell transplantation (HSCT). 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je navedena akutna limfoblastična leukemija (ALL) refrakterna i/ili recidiv ALL.
The neuronavigation-guided focused ultrasound system according to claim 1, wherein said fixture comprises a sliding track and a fixed track, and wherein said first tracking point is arranged on said fixed track, and wherein said second tracking point is arranged on said sliding track. 
Neuronavigacijski vođeni fokusirani ultrazvučni sustav prema zahtjevu 1, naznačen time što navedeni pribor za učvršćivanje obuhvaća kliznu tračnicu i nepomičnu tračnicu, te pri čemu je navedena prva točka praćenja postavljena na navedenu nepomičnu tračnicu, te pri čemu je navedena druga točka praćenja postavljena na navedenu kliznu tračnicu.
A method of treating a Btk-related disease selected from the group consisting of lupus, systemic lupus erythematosus, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, and juvenile arthritis, said method comprising administering to a mammal in need thereof an effective amount of 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride. 
Kristal prema bilo kojem od patentnih zahteva 2 do 5, ima endotermički vrh pri maksimalnoj temperaturi od 216°C u diferencijalnoj skenirajućoj kalorimetriji. Farmaceutska kompozicija sadrži 6-amino-9-[(3R)-1-(2-butinoil)-3-pirolidinil]-7-(4-fenoksifenil)-7,9-dihidro-8H-purin-8-on hidroklorid.
Headset apparatus according to any preceding claim in which the body of one of the headwear connection means and reciprocal connection means defines a channel, recess or opening (2) therein and the body of the other of the headwear and reciprocal connection means is shaped and arranged to fit intimately within said channel, recess or opening to abut the body of the connection means where it defines said channel, recess or opening. 
Slušalice prema bilo kojem od prethodnih zahtjeva, naznačene time, da se u trupu od jednog od naglavnog spojnog uređaja 1 recipročnog spojnog uređaja, definira kanal, udubina ili otvor (2), dok je trup od onog drugog naglavnog i Tecipročnog spojnog uređaja, oblikovan i namješten tako, da tijesno pristaje unutar navedenog kanala, udubine ili otvora, kako bi granično dodirivao trup od spojnog uređaja, tamo gdje se definira navedeni kanal, udubina ili otvor.
The control meter of claim 15, wherein the local control unit is arranged to transmit the tamper signal to the remote central control, if at the end of the power out condition the activation signal is present and if the duration of the power out condition exceeded a predetermined duration. 
Nadzorno brojilo iz patentnog zahtjeva 11, naznačeno time, da je lokalna nadzorna jedinica postavljena tako da prenosi signal o neovlaštenom baratanju u udaljenu središnju nadzornu jedinicu, ako nakon stanja nestanka struje i dalje postoji aktivacijski signal i trajanje stanja nestanka struje prelazi unaprijed određeno trajanje.
The second aspect of the present invention provides: An immunogenic composition as above, wherein the saponin is present in an amount of about 1 ug to about 5,000 ug per dose, the sterol is present in an amount of about 1 ug to about 5,000 ug per dose, the quaternary ammonium compound is present in an amount of about 1 ug to about 5,000 ug per dose, and the polymer is present in an amount of about 0.0001% volume to volume (v/v) to about 75% v/v. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedeni Quil A ili njegova pročišćena fakcija prisutan u količini od otprilike 1 ug do otprilike 5.000 ug po dozi, sterol je prisutan u količini od otprilike 1 ug do otprilike 5.000 ug po dozi, DDA je prisutan u količini od otprilike 1 ug do otprilike 5.000 ug po dozi, a polimer od poliakrilne kiseline je prisutan u količini od otprilike 0,0001% vol./vol. do otprilike 75% vol./vol.
The method of claim 1, wherein the culture medium comprises about 5 uM zinc. The method of claim 1, wherein the culture medium comprises from 4 mg/L to 10 mg/L nicotinamide. 
Metoda u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu medij za kultiviranje nadalje sadrži najmanje 2 mg/L nikotinamida (vitamina B3), poželjno najmanje 7 mg/L nikotinamida (vitamina B3).
The magnesia cement of claim 1 or 2, characterized in that the carboxylic acid component has a solubility at 20°C of from 0.5 to 50, preferably of from 1 to 20 g/L, or a dissolution rate in an aqueous solution at 20°C of from 1 to 50 g/L/h, preferably of from 2 to 20 g/L/h. 
Magnezijski cement prema zahtjevu 1 ili 2, naznačen time što sastojak karboksilne kiseline ima topljivost na 20%C od 1 do 20 g/L, ili brzinu otapanja u vodenoj otopini na 20*C€ od 2 do 20 g/L/h.
and R4, taken together with the adjacent nitrogen atom, form an azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl, the piperydinyl ring being optionally substituted with one or two (C1-C2)alkyl group(s) and the piperazinyl ring being optionally substituted on the other N-atom with a (C1-C4)alkyl, benzyl, or phenylsulfonyl group; or a pirrolidinyl, piperidinyl, morpholinyl or piperazinyl ring fused with a benzene ring; 
i R4, uzeti zajedno sa susjednim dušikovim atomom tvore azetidinilni, pirolidinilni, morfolinilni, piperidinilni ili piperazinilni prsten, a piperidinilni prsten može biti supstituiran s jednom ili dvjema (C1-C2)alkilnim skupinama te piperazinilni prsten može biti supstituiran na drugom N-atomu s (C1-C4)alkilnom, benzilnom ili fenilsulfonilnom skupinom; ili pirolidinilni, piperidinilni, morfolinilni ili piperazinilni prsten fuzioniran s benzenskim prstenom;
A compound for use as a polymerization agent in coatings, the compound comprising a cobalt-bearing alkyd polymer, the polymer comprising cobalt carboxylate as a repeating unit and having a cobalt content of 0.5 to 6% by weight, a mean molecular weight of more than 3000, and an acidity value of less than 30 mg KOH/g. 
Spoj za upotrebu kao sredstvo za polimerizaciju u premazima, koji sadrži alkidni polimer s kobaltom sa sadržajem kobalta od 0,5 do 6 % po masi, s prosječnom molekulskom masom većom od 3000 1 s karboksilatnim sekvencama kobalta, čija je značajka to što navedeni polimer ima kiselost manju od 40 mg KOH/g, a poželjno manju od 20 mg KOH/g.
A process for preparing interleukin-2 for pharmaceutical use, comprising the steps of: (a) adding sodium dodecyl sulfate (SDS) to a composition comprising interleukin-2, to give a final SDS concentration of at least 500µg SDS per mg of IL-2; (b) reducing the SDS concentration to remove some but not all SDS from the composition, to give a composition that contains between 95-250µg SDS per mg of interleukin-2. 
Proces za pripremu interleukina-2 za farmaceutsku uporabu, naznačen time, da se sastoji od stupnjeva: (a) dodavanje natrij dodecil sulfata (SDS - Sodium Dodecyl Sulfate) sastavu koji sadrži IL-2 s intramolekularnim disulfidnim vezama, da dade konačnu koncentraciju SDS od barem 500ug SDS po mg IL-2; (b) odstranjivanje bilo kojeg od istaloženih kovalentno vezanih IL-2 multimera pomoću gel filtracije; i (c) smanjivanje koncentracije SDS da se odstrani nešto, ali ne sav SDS iz sastava, da dade sastav koji sadrži između 95-250ug SDS po mg IL-2.
or a pharmaceutically acceptable salt thereof, wherein Y is O or NH. 
Spoj izabran od sljedećih spojeva, ili njegova farmaceutski prihvatljiva sol:
adding to the mixture egg yolk phospholipids; and adding an aqueous phase; wherein the pH is adjusted to about 6 to about 8.8; 
gdje je pH je podešen na od oko 6 do oko 8.8; i homogeniziranje emulzije; i gdje je količina proizvoda razgradnje sa formulom:
Use according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 1000 to 5000 mg, and more preferably of 1300 to 2000 mg, per liter of the aqueous phase of said suspension. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni 2-((1-metilpropil)amino)etanol dodan u navedenu suspenziju u količini od 1000 do 5000 mg, poželjnije od 1300 do 2000 mg, po litri vodene faze navedene suspenzije.
The dsRNA of any one of claims 1 to 5, wherein said dsRNA comprises at least one modified nucleotide, wherein preferably at least one of said modified nucleotides is chosen from the group of: a 2'-O-methyl modified nucleotide, a nucleotide comprising a 5'-phosphorothioate group, a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group, a 2'-deoxy-2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2'-amino-modified nucleotide, 2'-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. 
dsRNA prema bilo kojem zahtjevu od 1 do 3, naznačena time da navedena dsRNA sadrži barem jedan modificirani nukleotid. dsRNA prema zahtjevu 4, naznačena time da je barem jedan od navedenih modificiranih nukleotida odabran iz skupine koja sadrži: 2'-O-metil modificirani nukleotid, nukleotid koji sadrži 5'-fosforotioatnu skupinu, terminalni nukleotid povezan derivatom kolesterila ili bisdecilamidnu skupinu dodekanske kiseline, 2'-deoksi-2'-fluoro modificirani nukleotid, 2'-deoksi-modificirani nukleotid, zaključan nukleotid, abazni nukleotid, 2'-amino-modificirani nukleotid, 2'-alkil-modificirani nukleotid, morfolino nukleotid, fosforamidat, te nukleotid koji sadrži neprirodnu bazu.
The composition according to claim 7, wherein said at least one additional active compound is selected from baclofen, mifepristone, sorbitol, naltrexone, rapamycin, ketoprofen and flurbiprofen. 
Sastav u skladu s patentnim zahtjevom 7, pri čemu je navedena barem jedna dodatna aktivna tvar odabrana između baklofena, mifepristona, sorbitola, naltreksona, rapamicina, ketoprofena i flurbiprofena.
Further still, the instrument preferably comprises a suturing device adapted to suture the opening of the tube-like portion with stomach to stomach sutures for creating at least partly a closed space enclosing the volume filling device, wherein the instrument is adapted to be withdrawn leaving the volume filling device at least partly invaginated in the stomach wall. Said suturing device preferably comprises a first and second suture positioning member provided on the elongated member situated in the stomach at the distal end thereof, and wherein the instrument further comprises an operation device adapted to adjust the first and second suturing member in a position in which the first and second suture positioning members are in front of each other with the stomach wall on both sides of the open end of the cup like portion, and adapted to suture the open end of the cup like portion of the wall with a row of stomach to stomach sutures. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što uređaj za rastezanje ima prvi međudjelujući element (10"; 110a; 210a; 410b), prilagođen za međudjelovanje s prvim dijelom stijenke želuca, i drugi međudjelujući element (10"; 110b; 2106; 410b), prilagođen za međudjelovanje s drugim dijelom stijenke želuca, blizu, no odvojen od prvog dijela želuca, gdje je uređaj za rukovanje prilagođen za rukovanje prvim i drugim međudjelujućim elementom kako bi ih se razmaknulo jednog od drugog, kada međudjelujući elementi međudjeluju s prvim i drugim dijelom želuca kako bi rastegnuli dio stijenke želuca između prvog i drugog dijela želuca, tako da se postigne privremeni osjećaj sitosti.
(1.02 mm) in diameter. 
Uzdužni prolaz bio je promjera 1.02 mm.
The reaction mixture was cooled and filtered. 
Reakcijska smjesa se ohladi i filtrira.
the first injector mold plate face (4) faces towards the first ejector mold plate face (6), characterised in that the injection mold (1) comprises 
prva strana (4) kalupa za injektiranje okrenuta je prema prvoj strani (6) kalupa za izbacivanje,
or a pharmaceutically acceptable salt or prodrug thereof, wherein: 
[image] ili njena farmaceutski prihvatljiva sol, pri čemu:
The method according to claim 6, wherein the inorganic oxoacid compound and/or its salt are polyphosphoric acids and/or their salts, represented by general formula (Ia) 
Postupak prema zahtjevu 5, pri čemu su neorgansko oksokiselinski spoj i/ili njegova sol polifosforne kiseline i/ili njihove soli, predstavljene općom formulom (Ia)
However the presence of an abstinence syndrome is not the most essential component of addiction, as addiction is "a behavioral pattern characterized by compulsive use of a drug and overwhelming involvement with its procurement and use" despite known harmful effects (Goodman & Gillman's The Pharmacological Basis of Therapeutics, J.G. Hardman (Ed.), McGraw-Hill Professional Publishing, 2001, p.586). 
Ipak, prisutnost apstinencijskog sindroma nije najbitnija komponenta ovisnosti, pošto je ovisnost "uzorak ponašanja karakteriziran kompulzivnom upotrebom droge te neodoljivim angažiranjem oko njene nabave i upotrebe" usprkos poznatim štetnim učincima (Goodman & Gillman, The Pharmacological Basis of Therapeutics, J. G. Hardman (Ur.), McGraw-Hill Professional Publishing, 2001, p. 586).
The method of embodiment 55 wherein said skin disorder is atopic dermatitis or psoriasis. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da je navedeni kožni poremećaj atopijski dermatitis ili psorijaza.
Vitamin E or ester thereof 
Vitamin E ili njegov ester
A malonate salt of formula III or a hydrate thereof: 
Malonat formule III ili hidrat te soli:
The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein Ring A is R1a is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R2a and R3a are hydrogen atoms; R4a is a phenyl group substituted by a halogen atom, a cyano group, a C1-6 alkyl group, a halo-C1-6 alkyl group, a C1-6 alkoxy group, a halo-C1-6 alkoxy group, and a mono- or di-C1-6 alkylamino group; or a heterocyclyl group substituted by a halogen atom, a cyano group, a C1-6 alkyl group, or a C1-6 alkoxy group; and Y is -CH2-. 
a je atom halogena, C1-6 alkilna skupina ili C1-6 alkoksi skupina; a i R3a su atomi vodika; a je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C1-6 alkilnom skupinom, halogen-C1-6 alkilnom skupinom, C1-6 alkoksi skupinom, halogen-C1-6 alkoksi skupinom, te mono- ili di-C1-6 alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, C1-6 alkilnom skupinom ili C1-6 alkoksi skupinom; i Y je -CH2-.
Such viral infectious organisms include, but are not limited to, hepatitis type A, hepatitis type B, hepatitis type C, influenza, varicella, adenovirus, herpes simplex type I (HSV-1), herpes simplex type 2 (HSV-2), rinderpest, rhinovirus, echovirus, rotavirus, respiratory syncytial virus, papilloma virus, papilloma virus, cytomegalovirus, echinovirus, arbovirus, huntavirus, coxsackie virus, mumps virus, measles virus, rubella virus, polio virus and human immunodeficiency virus type I or type 2 (HIV-1, HIV-2). 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od infektivne bolesti uzrokovane virusom izabranim između hepatitia tipa A, hepatitisa tipa B, hepatitisa tipa C, influence, varicella, adenovirusa, herpesa simpleksa tipa I (HSV-1), herpesa simpleksa tipa 2 (HSV-2), rinderpesta, rinovirusa, echovirusa, rotavirusa, respiratornog sincicijskog virusa, papilloma virusa, citomegaloviruas, arbovirusa, huntavirusa, coxsackie virusa, virusa zaušnjaka, virusa ospica, rubella viruas, polio virusa ili virusa humane imunodeficijencije tipa tipa I ili tipa 2 (HIV-1, HIV-2).
The oral formulation according to anyone of claims 1 to 8 characterized by an improved absorption profile over the Medium Chain Triglycerides (MCT) formulation of said 14-epi-analogue of vitamin D. 
Oralna formulacija prema bilo kojem patentnom zahtjevu od 1 do 5, naznačena time da ima poboljšani apsorpcijski profil u odnosu na formulaciju inekalcitola sa srednjolančanim trigliceridima (MCT).
The method of E 1, wherein the AOID is uveitis. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 1, naznačen time, da AOID je uveitis.
the second antibody H chain consists of SEQ ID NO: 25; and 
(a1) H-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 1;
and R4 are each independently H, halogen, perhaloalkyl, CN, OR5, SR5, NHR5, N(R5)2, OH, aryl, or heteroaryl, wherein said aryl is optionally substituted with up to two substituents selected from C1-8 alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl is optionally substituted with up to two substituents selected from halogen and C1-8 alkyl; 
i R4 su svaki neovisno H, halogen, perhaloalkil, CN, OR5, SR5, NHR5, N(R5)2, OH, aril ili heteroaril pri čemu je navedeni aril po izboru supstituiran sve do sa po dva supstituenda izabrana iz skupine koju čine C1-8alkil, halogen, perhalo alkil i alkoksi te je navedeni heteroaril po izboru supstituiran sve do sa po dva supstituenda izabrana iz skupine koju čine halogen i C1-8alkil;
reacting crude Compound 8 with a metal bisulfite to produce Compound 9: 
(b) reakciji sirovog Spoja 8 s metalnim bisulfitom kako bi se dobilo Spoj 9:
The video decoding method of claim 1, wherein the maximum split information for the intra mode and the maximum split information for the inter mode are obtained as parameters with respect to one data level from among data levels comprising a picture sequence, a picture, a slice, and a data unit for encoding a video. 
Uređaj za dekodiranje video zapisa prema zahtjevu 1, naznačen time što se informacija o maksimalnom dijeljenju za transformacijsku jedinicu s intra načinom dobije kao parametri u odnosu na jednu razinu podataka između razina podataka koje sadrže niz slika, sliku, odsječak, 1 jedinicu podataka za kodiranje videa.
the antibody is for use according to claim 20(c), wherein the osteopenic disorder is selected from the group consisting of osteopenia, osteoporosis, periodontitis, Paget's disease, bone loss due to immobilization, lytic bone metastases, and arthritis. 
(b) protutijelo je namijenjeno upotrebi u skladu s patentnim zahtjevom 20(c), gdje se osteopenični poremećaj bira iz skupine koju čine osteopenija, osteoporoza, periodontitis, Pagetova bolest, gubitak kostiju zbog imobilizacije, litičke metastaze u kostima, te artritis.
A compound according to claim 1, wherein R2 and R′2, together with the nitrogen atom to which they are linked, form a morpholinyl group. 
Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da R, i R2, zajedno sa atomom dušika na koji su spojeni, formiraju morfolinilnu skupinu.
The method of claim 1 wherein the composition comprises (by approximate weight percent) emtricitabine 30.6, tenofovir DF 46.0, microcrystalline cellulose 13.7, croscarmellose sodium 7.3 and magnesium stearate 2.2. 
Postupak prema patentnom zahtjevu 1, naznačen time što kompozicija sadrži (približno u težinskim postocima) emtricitabin 30.6, tenofovir DF 46.0, mikrokristalnu celulozu 13.7, kroskarmeloza natrij 7.3 i magnezijev stearat
The compound in which R4 is C1-6 alkyl which may be substituted with -O-C1-6 alkyl. 
R* predstavlja C;.4 alkil koji može biti supstituiran sa sljedećima: fenil, cikloalkil ili -H,
The method of claim 2 where the daily dose of the seladelpar or a salt thereof administered to the subject is 20-200 mg, when the dose is calculated as seladelpar. 
Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da dnevna doza spoja (kada se računa kao slobodna kiselina) iznosi od 20 do 200 mg.
Whenever the word “between” or “to” is used to describe a numerical range, it is to be understood that the end points of the indicated range are explicitly included in the range. 
Farmaceutski sastav prema zahtjevu 4, naznačen time, da se upotrebljava u liječenju ili prevenciji bolesti ili poremećaja mentalnog zdravlja u odnosu na oreksinergijske disfunkcije.
(BN) The Compound of Paragraph (AA) where R2 is hydrogen, R4 is methyl, R1 is optionally substituted alkyl or cycloalkyl, and R6 is heteroaryl optionally substituted with 1, 2, 3, 4, or 5 R9 groups. (BO) The Compound of Paragraph (AY) where R1 is heterocycloalkyl or heterocycloalkylalkyl and R4 is methyl. 
Spoj prema patentnom zahtjevu 1, naznačen time što je R* jednako vodik, R* je metil, R! je izborno supstituirani alkil ili cikloalkil, i R" je heteroaril izborno supstituiran sa 1, 2, 3, 4 ili 5 R? grupa; ili njegov pojedinačni stereoizomer ili smjesa stereoizomera i izborno kao njegova farmaceutski prihvatljiva sol ili solvat.
A method of preparation of the compound according to claims 1-8, characterized in that trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7] oxepino [4,5-c] pyrrole (Z)-2-butenedioate is crystallized from an ethanol/water mixture. 
Postupak za dobivanje spoja prema Zahtjevima 1-8, naznačen time, da je trans-5-kloro-2,3,3a, 12b-tetrahidro-2-metil-1H-dibenz [2,3:6,7] oksepino [4,5-c] pirol (Z)-2-butendioat kristaliziran iz smjese etanol/voda.
The mixture was stirred over night at room temperature. 
Mješavina je miješana preko noći na sobnoj temperaturi.
Use of a compound of formula I in the manufacture of a medicament for treating type II diabetes. 
Primjena spoja formule I, naznačena time što se koristi proizvodnji lijeka za liječenje dijabetesa tipa II.